Clinical Trial Update: PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA) [Phase 1]

View source ↗

Summary

Phase 1 PANAMA trial evaluating a dual NAMPT/PAK4 inhibitor in patients with solid tumors or non-Hodgkin lymphoma was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma
• Solid Tumors

Drugs mentioned

• KPT-9274 (KPT-9274)

Snippet

Sponsor: Karyopharm Therapeutics Inc | Conditions: Solid Tumors, NHL | Phase 1 | Status: TERMINATED | Results posted: 2024-11-25